162 related articles for article (PubMed ID: 9354001)
21. Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancer.
Hautmann S; Huland E; Grupp C; Haese A; Huland H
Anticancer Res; 2000; 20(3B):2151-4. PubMed ID: 10928169
[TBL] [Abstract][Full Text] [Related]
22. [Modifications of lactate-dehydrogenase-isoenzyme serum levels in breast diseases].
Mazzarino C; Pisana C; Morello G; Di Benedetto A
Boll Soc Ital Biol Sper; 1977 Apr; 53(7):569-74. PubMed ID: 911514
[No Abstract] [Full Text] [Related]
23. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
Ogawa Y; Ishikawa T; Ikeda K; Nakata B; Sawada T; Ogisawa K; Kato Y; Hirakawa K
Clin Cancer Res; 2000 Oct; 6(10):4069-72. PubMed ID: 11051258
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance of serum ferritin and acute phase reactant proteins levels in patients with cervical cancer].
Xie JF
Zhonghua Fu Chan Ke Za Zhi; 1991 Mar; 26(2):92-4, 124. PubMed ID: 1713541
[TBL] [Abstract][Full Text] [Related]
25. [Relation of blood serum ferritin and ferritin-bearing lymphocytes in breast cancer].
Chernovskaia EM; Polevaia EB; Tuzhikova NK
Med Radiol (Mosk); 1986 Apr; 31(4):15-7. PubMed ID: 3959805
[TBL] [Abstract][Full Text] [Related]
26. Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease.
Zanetti-Dällenbach R; Wight E; Fan AX; Lapaire O; Hahn S; Holzgreve W; Zhong XY
Anticancer Res; 2008; 28(2A):921-5. PubMed ID: 18507037
[TBL] [Abstract][Full Text] [Related]
27. Impact of inflammatory markers on the prognosis of patients with operable breast cancer.
Petekkaya I; Aksoy S; Roach EC; Okoh AK; Gecmez G; Gezgen G; Isler DC; Dogan E; Babacan T; Sarici F; Petekkaya E; Altundag K
J BUON; 2014; 19(3):673-80. PubMed ID: 25261651
[TBL] [Abstract][Full Text] [Related]
28. Total and lipid-bound serum sialic acid in benign and malignant breast disease.
Romppanen J; Eskelinen M; Tikanoja S; Mononen I
Anticancer Res; 1997; 17(2B):1249-53. PubMed ID: 9137482
[TBL] [Abstract][Full Text] [Related]
29. [Value of interleukin-8 determination in diagnosis of benign and malignant breast tumor].
Zakrzewska I; Kozłowski L; Wojtukiewicz M
Pol Merkur Lekarski; 2002 Oct; 13(76):302-4. PubMed ID: 12557436
[TBL] [Abstract][Full Text] [Related]
30. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
31. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
32. Results of the determination of serum markers in patients with malignant melanoma.
Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
[TBL] [Abstract][Full Text] [Related]
33. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
[TBL] [Abstract][Full Text] [Related]
34. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer.
Yang DC; Wang F; Elliott RL; Head JF
Anticancer Res; 2001; 21(1B):541-9. PubMed ID: 11299801
[TBL] [Abstract][Full Text] [Related]
35. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer.
Somiari SB; Shriver CD; Heckman C; Olsen C; Hu H; Jordan R; Arciero C; Russell S; Garguilo G; Hooke J; Somiari RI
Cancer Lett; 2006 Feb; 233(1):98-107. PubMed ID: 16473671
[TBL] [Abstract][Full Text] [Related]
36. Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors.
Erić-Nikolić A; Matić IZ; Dorđević M; Milovanović Z; Marković I; Džodić R; Inić M; Srdić-Rajić T; Jevrić M; Gavrilović D; Cordero OJ; Juranić ZD
Immunobiology; 2011 Aug; 216(8):942-6. PubMed ID: 21281985
[TBL] [Abstract][Full Text] [Related]
37. Serum big endothelin-1 levels in female patients with breast cancer.
Yildirim Y; Gunel N; Coskun U; Sancak B; Bukan N; Aslan S; Cetin A
Int Immunopharmacol; 2008 Aug; 8(8):1119-23. PubMed ID: 18550016
[TBL] [Abstract][Full Text] [Related]
38. LDH isoenzymes in the serum of patients with malignant diseases.
Roguljić A; Demirović J
Acta Med Iugosl; 1980 Nov; 34(4):315-24. PubMed ID: 7468308
[No Abstract] [Full Text] [Related]
39. Importance of serum prolactin determination in metastatic breast cancer patients.
Mujagić Z; Mujagić H
Croat Med J; 2004 Apr; 45(2):176-80. PubMed ID: 15103755
[TBL] [Abstract][Full Text] [Related]
40. [The significance of lactate dehydrogenase isoenzymes in malignant breast tumors].
Demirović J; Roguljić A; Nola P
Lijec Vjesn; 1982; 104(7-8):307-11. PubMed ID: 7144421
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
